Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer

Cytokine

Volumn 65, Issue 2, 2014, Pages 192-201

  Merriman, John D ^a   Aouizerat, Bradley E ^b   Cataldo, Janine K ^b   Dunn, Laura ^c   Cooper, Bruce A ^b   West, Claudia ^b   Paul, Steven M ^b   Baggott, Christina R ^b   Dhruva, Anand ^c   Kober, Kord ^b   Langford, Dale J ^b   Leutwyler, Heather ^b   Ritchie, Christine S ^c   Abrams, Gary ^c   Dodd, Marylin ^b   Elboim, Charles ^d   Hamolsky, Deborah ^b   Melisko, Michelle ^c   Miaskowski, Christine ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Redwood Regional Medical Group   (United States)

Author keywords

Attention; Breast cancer; Cytokine genes; Inflammation; Interleukin 1 receptor, type I

Indexed keywords

DNA; INTERLEUKIN 1 RECEPTOR;

ADULT; AGE; ALLELE; ARTICLE; ATTENTION; BREAST CANCER; COMORBIDITY; CONTROLLED STUDY; DNA DETERMINATION; ETHNICITY; FUNCTIONAL STATUS; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; INTERLEUKIN 1 RECEPTOR GENE; MAJOR CLINICAL STUDY; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM;

AFI; AIMS; ANCESTRY INFORMATIVE MARKERS; ATTENTION; ATTENTIONAL FUNCTION INDEX; BAYESIAN INFORMATION CRITERION; BIC; BLRT; BMI; BODY MASS INDEX; BOOTSTRAPPED LIKELIHOOD RATIO TEST; BREAST CANCER; CENTRAL NERVOUS SYSTEM; CI; CNS; CONFIDENCE INTERVAL; CYTOKINE GENES; DEOXYRIBONUCLEIC ACID; DNA; GMM; GROWTH MIXTURE MODELING; INFLAMMATION; INTERLEUKIN 1 RECEPTOR, TYPE I; KARNOFSKY PERFORMANCE STATUS; KPS; LD; LINKAGE DISEQUILIBRIUM; MAF; MINOR ALLELE FREQUENCY; ODDS RATIO; OR; SCQ; SELF-ADMINISTERED COMORBIDITY QUESTIONNAIRE; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; VLMR; VUONG-LO-MENDELL-RUBIN LIKELIHOOD RATIO TEST;

ALLELES; ATTENTION; BREAST NEOPLASMS; DEMOGRAPHY; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MODELS, BIOLOGICAL; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, INTERLEUKIN-1 TYPE I; SELF REPORT;

EID: 84892476325     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.11.003     Document Type: Article

References (70)

1. Cimprich B., Visovatti M., Ronis D.L. The attentional function index - a self-report cognitive measure. Psychooncology 2011, 20:194-202.
2. Myers J.S. Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 2012, 39:E31-E40.
3. Boykoff N., Moieni M., Subramanian S.K. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 2009, 3:223-232.
4. Gazzaley A., Nobre A.C. Top-down modulation: bridging selective attention and working memory. Trends Cogn Sci 2012, 16:129-135.
5. Lezak M.D. Neuropsychological assessment 2012, Oxford University Press, New York. 5th ed.
6. Ferguson R.J., McDonald B.C., Saykin A.J., Ahles T.A. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007, 25:3866-3870.
7. Reuter-Lorenz P.A., Cimprich B. Cognitive function and breast cancer: promise and potential insights from functional brain imaging. Breast Cancer Res Treat 2013, 137:33-43.
8. Wefel J.S., Vardy J., Ahles T., Schagen S.B. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011, 12:703-708.
9. Seruga B., Zhang H.B., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008, 8:887-899.
10. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011, 130:226-238.
11. Watkins L.R., Goehler L.E., Relton J.K., Tartaglia N., Silbert L., Martin D., et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995, 183:27-31.
12. Banks W.A., Erickson M.A. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 2010, 37:26-32.
13. Plotkin S.R., Banks W.A., Kastin A.J. Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood-brain barrier. J Neuroimmunol 1996, 67:41-47.
14. Konsman J.P., Vigues S., Mackerlova L., Bristow A., Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol 2004, 472:113-129.
15. D'Mello C., Le T., Swain M.G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci 2009, 29:2089-2102.
16. Joshi G., Sultana R., Tangpong J., Cole M.P., St Clair D.K., Vore M. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res 2005, 39:1147-1154.
17. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., Miller A.H. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 2010, 15:535-547.
18. Tong L., Balazs R., Soiampornkul R., Thangnipon W., Cotman C.W. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging 2008, 29:1380-1393.
19. Wilson C.J., Finch C.E., Cohen H.J. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002, 50:2041-2056.
20. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7:192-201.
21. Merriman J.D., Aouizerat B.E., Langford D.J., Cooper B.A., Baggott C.R., Cataldo J.K., et al. Preliminary evidence of an association between an interleukin 6 promoter polymorphism and self-reported attentional function in oncology patients and their family caregivers. Biol Res Nurs 2013.
22. McCann B., Miaskowski C., Koetters T., Baggott C., West C., Levine J.D., et al. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain 2012, 13:425-437.
23. Karnofsky D. Performance scale 1977, Plenum Press, New York.
24. Sangha O., Stucki G., Liang M.H., Fossel A.H., Katz J.N. The Self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003, 49:156-163.
25. Cimprich B., So H., Ronis D.L., Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology 2005, 14:70-78.
26. Cimprich B. Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs 1999, 22:185-194.
27. Lehto R.H., Cimprich B. Anxiety and directed attention in women awaiting breast cancer surgery. Oncol Nurs Forum 1999, 26:767-772.
28. Cimprich B. Attentional fatigue following breast cancer surgery. Res Nurs Health 1992, 15:199-207.
29. Jansen C.E., Cooper B.A., Dodd M.J., Miaskowski C.A. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 2011, 19:1647-1656.
30. Chen M.L., Miaskowski C., Liu L.N., Chen S.C. Changes in perceived attentional function in women following breast cancer surgery. Breast Cancer Res Treat 2012, 131:599-606.
31. Von Ah D., Russell K.M., Storniolo A.M., Carpenter J.S. Cognitive dysfunction and its relationship to quality of life in breast cancer survivors. Oncol Nurs Forum 2009, 36:326-336.
32. Dunn L.B., Aouizerat B.E., Cooper B.A., Dodd M., Lee K., West C., et al. Trajectories of anxiety in oncology patients and family caregivers during and after radiation therapy. Eur J Oncol Nurs 2012, 16:1-9.
33. Cohen J. Statistical power analysis for the behavioral sciences 1988, L. Erlbaum Associates, Hillsdale, NJ. 2nd ed.
34. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
35. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
36. Miaskowski C., Cooper B.A., Dhruva A., Dunn L.B., Langford D.J., Cataldo J.K., et al. Evidence of associations between cytokine genes and subjective reports of sleep disturbance in oncology patients and their family caregivers. PLoS ONE 2012, 7:e40560.
37. Halder I., Shriver M., Thomas M., Fernandez J.R., Frudakis T. A panel of ancestry informative markers for estimating individual biogeographical ancestry and admixture from four continents: utility and applications. Hum Mutat 2008, 29:648-658.
38. Hoggart C.J., Parra E.J., Shriver M.D., Bonilla C., Kittles R.A., Clayton D.G., et al. Control of confounding of genetic associations in stratified populations. Am J Hum Genet 2003, 72:1492-1504.
39. Tian C., Gregersen P.K., Seldin M.F. Accounting for ancestry: population substructure and genome-wide association studies. Hum Mol Genet 2008, 17:R143-R150.
40. Dunn L.B., Aouizerat B.E., Langford D.J., Cooper B.A., Dhruva A., Cataldo J.K., et al. Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers. Eur J Oncol Nurs 2013, 17:346-353.
41. Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology 1990, 1:43-46.
42. Hattersley A.T., McCarthy M.I. What makes a good genetic association study?. Lancet 2005, 366:1315-1323.
43. Jung T., Wickrama K.A.S. An introduction to latent class growth analysis and growth mixture modeling. Soc Person Psychol Compass 2008, 2:302-317.
44. Wyrwich K.W., Bullinger M., Aaronson N., Hays R.D., Patrick D.L., Symonds T., et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005, 14:285-295.
45. Hagedoorn M., Buunk B.P., Kuijer R.G., Wobbes T., Sanderman R. Couples dealing with cancer: role and gender differences regarding psychological distress and quality of life. Psychooncology 2000, 9:232-242.
46. Walsh D., Donnelly S., Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Support Care Cancer 2000, 8:175-179.
47. Reyes-Gibby C.C., Aday L.A., Anderson K.O., Mendoza T.R., Cleeland C.S. Pain, depression, and fatigue in community-dwelling adults with and without a history of cancer. J Pain Symptom Manage 2006, 32:118-128.
48. Illi J., Miaskowski C., Cooper B., Levine J.D., Dunn L., West C., et al. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine 2012, 58:437-447.
49. Hagedoorn M., Sanderman R., Bolks H.N., Tuinstra J., Coyne J.C. Distress in couples coping with cancer: a meta-analysis and critical review of role and gender effects. Psychol Bull 2008, 134:1-30.
50. Merriman J.D., Jansen C., Koetters T., West C., Dodd M., Lee K., et al. Predictors of the trajectories of self-reported attentional fatigue in women with breast cancer undergoing radiation therapy. Oncol Nurs Forum 2010, 37:423-432.
51. Merriman J.D., Dodd M., Lee K., Paul S.M., Cooper B.A., Aouizerat B.E., et al. Differences in self-reported attentional fatigue between patients with breast and prostate cancer at the initiation of radiation therapy. Cancer Nurs 2011, 34:345-353.
52. Bauer L.C., Johnson J.K., Pozehl B.J. Cognition in heart failure: an overview of the concepts and their measures. J Am Acad Nurse Pract 2011, 23:577-585.
53. Hauksdottir A., McClure C., Jonsson S.H., Olafsson O., Valdimarsdottir U.A. Increased stress among women following an economic collapse-a prospective cohort study. Am J Epidemiol 2013.
54. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
55. Libermann T.A., Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990, 10:2327-2334.
56. Napetschnig J., Wu H. Molecular basis of NF-kappaB signaling. Annu Rev Biophys 2013, 42:443-468.
57. Courtois G., Gilmore T.D. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006, 25:6831-6843.
58. Database of Single Nucleotide Polymorphisms (dbSNP), dbSNP accession: rs949963 (dbSNP Build ID: 86/137). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine, 2013.
59. Grabe N. AliBaba2.1. TRANSFAC; 2000. <. [retrieved 19.01.13]. http://www.gene-regulation.com.
60. Landvik N.E., Tekpli X., Anmarkrud K.H., Haugen A., Zienolddiny S. Molecular characterization of a cancer-related single nucleotide polymorphism in the pro-inflammatory interleukin-1B gene. Mol Carcinog 2012, 51(Suppl 1):E168-E175.
61. Gao J., Wang W.Y., Mao Y.W., Graff J., Guan J.S., Pan L., et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010, 466:1105-1109.
62. Ratajewski M., Walczak-Drzewiecka A., Salkowska A., Dastych J. Upstream stimulating factors regulate the expression of RORgammaT in human lymphocytes. J Immunol 2012, 189:3034-3042.
63. Isotalo K., Kok E.H., Luoto T.M., Haikonen S., Haapasalo H., Lehtimaki T., et al. Upstream transcription factor 1 (USF1) polymorphisms associate with Alzheimer's disease-related neuropathological lesions: Tampere autopsy study. Brain Pathol 2012, 22:765-775.
64. Torres R., Macdonald L., Croll S.D., Reinhardt J., Dore A., Stevens S., et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Annu Rheum Dis 2009, 68:1602-1608.
65. Zhu C.B., Lindler K.M., Owens A.W., Daws L.C., Blakely R.D., Hewlett W.A. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010, 35:2510-2520.
66. Engler H., Bailey M.T., Engler A., Stiner-Jones L.M., Quan N., Sheridan J.F. Interleukin-1 receptor type 1-deficient mice fail to develop social stress-associated glucocorticoid resistance in the spleen. Psychoneuroendocrinology 2008, 33:108-117.
67. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
68. Cibelli M., Fidalgo A.R., Terrando N., Ma D., Monaco C., Feldmann M., et al. Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol 2010, 68:360-368.
69. Posner M.I., Rothbart M.K., Sheese B.E. Attention genes. Dev Sci 2007, 10:24-29.
70. Schagen S.B., Das E., van Dam F.S. The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psychooncology 2009, 18:674-678.